Phase I study of APG-2575 now open at Linear Clinical Research

Phase I study of APG-2575 now open at Linear Clinical Research

A first in human study of the Bcl-2 inhibitor APG-2575 is now open at Linear Clinical Research. The first agent in class, venetoclax, is a highly effective treatment for patients with blood cancers such as chronic lymphocytic leukaemia, mantle cell lymphoma, Waldenstrom’s macroglobulinemia.

We are enrolling patients with  previously treated B-cell lymphoma, myeloma and acute myeloid leukaemia. For more details visit the trial homepage.

Share this post